Castle announces the publication of a study showing that the TissueCypher® Barrett's Esophagus Test helped guide risk-aligned management decisions for patients with non-dysplastic Barrett's esophagus (NDBE). In the study, clinicians changed their management recommendations 90% of the time after receiving TissueCypher results, including escalating management for all patients with intermediate- or high-risk results and de-escalating management for 84% of those with low-risk results. The study, titled "The Tissue Systems Pathology Test Guides Physician Recommendations for Patients With Non-Dysplastic Barrett's Esophagus: A Case Series From a Gastrointestinal Surgery Center," was published in Foregut: The Journal of the American Foregut Society and is linked in the press release: hubs.la/Q04ysy6F0

Castle announces the publication of a new study highlighting the challenges patients with atopic dermatitis (AD) experience in achieving their treatment goals and strong patient interest in molecular testing to help guide systemic therapy selection. "One thing came through clearly in this study: patients want better control of their disease and more information to help guide their treatment decisions," said study author Diego Ruiz Dasilva, M.D., board-certified dermatologist at Forefront Dermatology in Virginia Beach, Virginia. "AdvanceAD-Tx gives us an opportunity to bring objective molecular information into those conversations, helping personalize systemic treatment decisions and expedite the path to an effective therapy and symptom relief." Press Release: hubs.la/Q04ykTRl0

In case you needed any more reasons to get moving, physical activity has been inversely associated with the risk of several cancers (including esophageal cancer and esophageal adenocarcinoma), according to a study in BMC Gastroenterology. Read full study: hubs.la/Q04x91FZ0 #FallIntoHealthyHabits #EsophagealCancer #EAC

Another beautiful day for a walk, this time in Nashville at the recent Steps Against Melanoma Walk, which helped to honor loved ones, support those currently facing melanoma, and raise awareness about one of the most aggressive forms of skin cancer. Leah Eaton represented #TeamCastle, proud to support @AIMatMelanoma in fueling critical research, raising awareness, and empowering the community in the fight against #melanoma. #FallIntoHealthyHabits #CastleCares

Castle announces the opening of its new laboratory and office facility in Scottsdale, Arizona, and will commemorate the milestone with a grand opening celebration at the new facility, located at 8667 E. Hartford Drive, on Tuesday, October 6, 2026, at 3:30 pm MST. The new 55,000-square-foot facility expands Castle's operational footprint in Arizona to support growing test volumes and long-term growth. Press release: hubs.la/Q04y2V6L0

Fall is the perfect time to get outside and walk to support those affected by melanoma and raise awareness about one of the most aggressive forms of skin cancer. Castle was proud to support @AIMatMelanoma at their recent Steps Against Melanoma Walk in Louisville, helping to advance education, fund innovative research, and provide hope to melanoma patients and families across the country. Representing #TeamCastle: CarolAnn Motley and Louise Burke #FallIntoHealthyHabits #CastleCares

Castle announces the publication of a new decision modeling study showing that the TissueCypher Barrett's Esophagus test (TSP-9) can help better align Barrett's esophagus (BE) management with a patient's individual risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). Full press release: hubs.la/Q04xxXck0

TOMORROW: Castle's executive management is scheduled to present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 am ET. Details/registration: hubs.la/Q04xslwF0

We're ECSTATIC to have won more (consecutive) Top Workplaces awards! 🏆Healthcare Industry Top Workplace — 4th year in a row 🏆Arizona Top Workplace — 5th year in a row 🏆8 Culture Excellence Awards — Leadership, Professional Development, Purpose & Values, Work-Life Flexibility, Employee Appreciation, Compensation & Benefits, Employee Well-Being, and Innovation Castle also earned a 2026 Top Workplaces USA award earlier this year. #CastleCulture #TopWorkplaces #WeLoveOurPeople❤️

Castle Biosciences today announced the publication of a multi-center study in the Journal of the American Academy of Dermatology (JAAD) validating the integrated DecisionDx-SCC test result (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma (SCC). The study, titled "Validation of the integrated 40-gene expression profile (i40-GEP) which provides prognostic and adjuvant radiation benefit for high-risk cutaneous squamous cell carcinoma," evaluated the enhanced DecisionDx-SCC algorithm in an independent validation cohort of 572 patients with high-risk SCC. Press release: hubs.la/Q04x54BJ0

☀️Sun safety doesn't end with summer months, so keep your student sun-safe at school! #FallIntoHealthyHabits & #PracticeSafeSun by covering up/layering clothing and wearing sunscreen (clothing is the single most effective form of sun protection for the body). More #BackToSchool sun safety tips from The Skin Cancer Foundation @SkinCancerOrg: hubs.la/Q04x2nG-0

🚶Castle is stepping into fall, proudly supporting the recent @CureMelanoma Twin Cities Miles for Melanoma 5K walk, together helping raise more than $55,000 toward their goals to fund research, elevate early detection awareness, and promote sun safety. #MilesForMelanoma #FallIntoHealthyHabits #CastleCares

This is why patient education matters. Robin first learned about #TissueCypher through the Gastro Girl Podcast. She took what she learned back to her healthcare team — and later joined us to share her own Barrett’s esophagus journey. She told me: “I no longer feel like a ticking timebomb.” We talk a lot about views, downloads and reach. But sometimes we get to see the person behind the numbers. That’s the impact that matters most. ❤️ @CastleBio Access Robin's full Patient Voice Episode on YouTube bit.ly/4dolHFm or yoru favorite podcast player. #health #esophagealcancer #GERD #Barrettsesophagus

Friendly reminder as we wrap up #NationalEyeExamMonth👀: get your annual eye exam! Many eye diseases, such as uveal melanoma (the most common form of eye cancer), can have no symptoms, so regular exams, including dilated eye exams, are critical to early diagnosis. #LoveYourEyes #UvealMelanoma #OcularMelanoma #DecisionDxUM

#WhyCastle "I love being part of a team that truly supports each other and pushes for excellence every day." Jen Belesi, Regional Business Director for the Northeast, weighs in on why she loves working at Castle. #WhyCastle #CastleCulture #CastleCareers #WeLoveOurPeople❤️

Castle is now dually listed on Nasdaq Texas! The company maintains its primary listing on The Nasdaq Global Market, and its common stock began listing on Nasdaq Texas on August 17 under its existing ticker symbol, "CSTL." Nasdaq Texas is a newly established exchange designed to support public companies with strong ties to Texas and the broader region, while allowing issuers to maintain access to Nasdaq's global platform, technology and market infrastructure. Press release: hubs.la/Q04v0J9v0

Excellent panel discussion this morning at Future Biotech Expo 2026! Castle's own Dr. Hillary Caruso shared the stage to offer valuable insights into the future of precision healthcare, specifically how advanced diagnostics, data-driven innovation, emerging technologies, cross-functional collaboration, and strategic leadership are transforming biotechnology while accelerating earlier disease detection, improving patient outcomes, and shaping the future of global healthcare.

Only about half of U.S. adults get their recommended annual eye exams, but did you know that these exams can detect more than 270 health conditions? Routine eye exams help catch rare diseases such as uveal melanoma (the most common form of eye cancer) early, when treatment outcomes are better. August is #NationalEyeExamMonth👀, so love your eyes and get your annual eye exam! #LoveYourEyes #UvealMelanoma #OcularMelanoma #DecisionDxUM

Castle today announced that it has been approved to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas. Castle will maintain its primary listing on The Nasdaq Global Market, and its common stock is expected to begin listing on Nasdaq Texas today under its existing ticker symbol, "CSTL." Press release: hubs.la/Q04t98VS0

In this recent @InBusinessPHX article, Castle co-founder and COO Kristen Oelschlager shares how Greater Phoenix's bioscience community — from research institutions to organizations like AZBio — has helped shaped Castle's growth from a small startup into a diagnostics company serving patients nationwide. She also looks ahead to what it will take for the region to become an even stronger bioscience hub: more specialized talent, greater access to capital, and expanded lab space. Read more: inbusinessphx.com/healthcare…